Publications

2021

1. Tsumura R, Anzai T, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Antitumor effect of humanized anti‑tissue factor antibody‑drug conjugate in a model of peritoneal disseminated pancreatic cancer. Oncol Rep, 45(1):329-336, 2021.
2. Shiraishi T, Ikeda K, Tsukada Y, Nishizawa Y, Sasaki T, Ito M, Kojima M, Ishii G, Tsumura R, Saijou S, Koga Y, Yasunaga M, Matsumura Y. High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer. BMC Cancer, 21(1):302, 2021.

2020

1. Tsumura R, Koga Y, Hamada A, Kuwata T, Sasaki H, Doi T, Aikawa K, Ohashi A, Katano I, Ikarashi Y, Ito M, Ochiai A. The report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan. Cancer Sci, 111(9):3386-3394, 2020.
2. Takashima H, Koga Y, Tsumura R, Yasunaga M, Tsuchiya M, Inoue T, Negishi E, Harada M, Yoshida S, Matsumura Y. Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. J Control Release, 323:138-150, 2020.

2019

1. Koga Y, Ochiai A. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. Cells, 8(5):418, 2019.
2. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma rich allograft models. Cancer Sci, 110(10):3296-3305, 2019.
3. Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, Kagari T, Hirotani K, Yasunaga M, Matsumura Y, Doi T. U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer. Mol Cancer Therap, 18(11):2043-2050, 2019.
4. Koga Y, Tsumura R, Matsumura Y. Preclinical Studies of ADC Therapy for Solid Tumors. Cancer Drug Delivery Systems Based on the Tumor Microenvironment. Matsumura Y., Tarin D. (eds), Springer, Tokyo, 125-154, 2019.

2018

1. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. J Control Release, 284:49-56, 2018.

2017

1. Yamazaki N, Koga Y, Taniguchi H, Kojima M, Kanemitsu Y, Saito N, Matsumura Y. High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget, 8(4):6970-6983, 2017.
2. Fukuoka S, Kojima T, Koga Y, Yamauchi M, Komatsu M, Komatsuzaki R, Sasaki H, Yasunaga M, Matsumura Y, Doi T, Ohtsu A. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. Oncotarget, 8(7):11020-11029, 2017.
3. Takashima H, Tsuji A, Saga T, Yasunaga M, Koga Y, Kuroda J, Yano S, Kuratsu J, Matsumura Y. Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Sci Rep, 7(1):12341, 2017.
4. Koga Y. miRNAs are stable in several severe storage conditions and useful for molecular diagnostics. J Tumor Med Prev, 1(4): 555568, 2017.
5. Yamazaki N, Koga Y, Matsumura Y. MicroRNA analysis of colorectal cancer using fecal and tissue samples. RNA Dis, 4(3):e1592, 2017.
6. Yasunaga M, Manabe S, Tsuji A, Furuta M, Ogata K, Koga Y, Saga T, Matsumura Y. Development of antibody–drug conjugates using DDS and molecular imaging. Bioengineering, 4:78, 2017.

2016

1. Sugaya A, Hyodo I, Koga Y, Yamamoto Y, Takashima H, Sato R, Tsumura R, Furuya F, Yasunaga M, Harada M, Tanaka R, Matsumura Y. Utility of epirubicin-incorporating micelle tagged with anti-tissue factor antibody clone with no anticoagulant effect. Cancer Sci, 107(3):335-340, 2016.
2. Fujiwara Y, Furuta M, Manabe S, Koga Y, Yasunaga M, Matsumura Y. Imaging mass spectrometry for the precise design of antibody-drug conjugates. Sci Rep, 6:24954, 2016.
3. Kudo M, Yamamoto Y, Koga Y, Hamaguchi T, Akimoto T, Yasunaga M, Matsumura Y. Effect of combined treatment with micelle-incorporated cisplatin (NC-6004) and S-1 on human gastric cancer xenografts. Mol Clin Oncol, 5:817-822, 2016.

2015

1. Koga Y, Manabe S, Aihara Y, Sato R, Tsumura R, Iwafuji H, Furuya F, Fuchigami H, Fujiwara Y, Hisada Y, Yamamoto Y, Yasunaga M, Matsumura Y. Antitumor effect of anti-tissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Int J Cancer, 137(6):1457-1466, 2015.
2. Ahn J, Miura Y, Yamada N, Chida T, Liu X, Kim A, Sato R, Tsumura R, Koga Y, Yasunaga M, Nishiyama N, Matsumura Y, Cabral H, Kataoka K. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials, 39:23-30, 2015.
3. Yamamoto Y, Hyodo I, Koga Y, Tsumura R, Sato R, Obonai T, Fuchigami H, Furuya F, Yasunaga M, Harada M, Kato Y, Ohtsu A, Matsumura Y. Enhanced antitumor effect of anti-tissue factor (TF) antibody-conjugated epirubicin-incorporating polymeric micelles in human cancer xenografts with high TF expression. Cancer Sci, 106(5):627-634, 2015.
4. Tsumura R, Sato R, Furuya F, Koga Y, Yamamoto Y, Fujiwara Y, Yasunaga M, Matsumura Y. Feasibility study of the Fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool. Int J Oncol, 47(6) 2107-2114, 2015.